{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:21:16Z","timestamp":1793996476055,"version":"4.8.0"},"reference-count":36,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["Advanced Fellowship"],"award-info":[{"award-number":["Advanced Fellowship"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"accepted":{"date-parts":[[2023,7,5]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Paediatric-onset inflammatory bowel disease (IBD) is a complex and heterogenous condition. Incidence of disease in those aged &lt;18 years has doubled over the last 25 years, with concurrent increased prevalence and no decrease in disease severity. The tools available at diagnosis for investigation have developed over the last 10 years, including better utilisation of faecal calprotectin, improved small bowel imaging and video capsule endoscopy. Alongside this, management options have increased and include biological and small molecule therapies targeting alternative pathways (such as interleukin 12\/23, integrins and Janus kinase\/signal transducers and activators of transcription, JAK-STAT pathways) and better understanding of therapeutic drug monitoring for more established agents, such as infliximab. Dietary manipulation remains an interesting but contentious topic.<\/jats:p>\n                  <jats:p>This review summarises some of the recent developments in the diagnosis, investigation and management of IBD in children and young people. IBD is increasingly recognised as a continuum of disease, with a proportion of patients presenting with classical Crohn\u2019s disease or ulcerative colitis phenotypes. Future implementation of personalisation and stratification strategies, including clinical and molecular biomarkers, implementation of predictors of response and outcome and use of additional therapies, will continue to require working within clinical networks and multiprofessional teams.<\/jats:p>","DOI":"10.1136\/archdischild-2023-325668","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T13:29:12Z","timestamp":1689773352000},"page":"370-376","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":89,"title":["Inflammatory bowel disease: recent developments"],"prefix":"10.1136","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-8198","authenticated-orcid":false,"given":"James John","family":"Ashton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4721-0577","authenticated-orcid":false,"given":"R Mark","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"2024122723550890000_109.5.370.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2025-2"},{"key":"2024122723550890000_109.5.370.2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology"},{"key":"2024122723550890000_109.5.370.3","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/MPG.0000000000003511","article-title":"Incidence and prevalence of paediatric inflammatory bowel disease continues to increase in the south of England","volume":"75","author":"Ashton","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024122723550890000_109.5.370.4","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21797"},{"key":"2024122723550890000_109.5.370.5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318936"},{"key":"2024122723550890000_109.5.370.6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.21037\/tp.2018.12.03","article-title":"Personalising medicine in inflammatory bowel disease-current and future perspectives","volume":"8","author":"Ashton","year":"2019","journal-title":"Transl Pediatr"},{"key":"2024122723550890000_109.5.370.7","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-313060"},{"key":"2024122723550890000_109.5.370.8","first-page":"469","article-title":"Analysis and hierarchical clustering of blood results before diagnosis in pediatric inflammatory bowel disease","volume":"26","author":"Ashton","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2024122723550890000_109.5.370.9","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2014-307941"},{"key":"2024122723550890000_109.5.370.10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5114\/aoms.2014.43672","article-title":"Is faecal calprotectin equally useful in all Crohn\u2019s disease locations? A prospective, comparative study","volume":"11","author":"Stawczyk-Eder","year":"2015","journal-title":"Arch Med Sci"},{"key":"2024122723550890000_109.5.370.11","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000239"},{"key":"2024122723550890000_109.5.370.12","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2021-101897"},{"key":"2024122723550890000_109.5.370.13","doi-asserted-by":"crossref","first-page":"664722","DOI":"10.3389\/fped.2021.664722","article-title":"Capsule endoscopy in children","volume":"9","author":"Cohen","year":"2021","journal-title":"Front Pediatr"},{"key":"2024122723550890000_109.5.370.14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.07.023"},{"key":"2024122723550890000_109.5.370.15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.11.014"},{"key":"2024122723550890000_109.5.370.16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2468-1253(22)00337-5","article-title":"Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British society of gastroenterology and British society of paediatric gastroenterology, hepatology and nutrition","volume":"8","author":"Kammermeier","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122723550890000_109.5.370.17","doi-asserted-by":"crossref","unstructured":"van Rheenen PF , Aloi M , Assa A , et al . The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis 2020:jjaa161. doi:10.1093\/ecco-jcc\/jjaa161","DOI":"10.1093\/ecco-jcc\/jjaa161"},{"key":"2024122723550890000_109.5.370.18","unstructured":"Quality standards for specialist Paediatric Gastroenterology, Hepatology and nutrition [RCPCH]. Available: https:\/\/www.rcpch.ac.uk\/resources\/quality-standards-specialist-paediatric-gastroenterology-hepatology-nutrition [Accessed 14 Apr 2023]."},{"key":"2024122723550890000_109.5.370.19","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous Infliximab [CT-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024122723550890000_109.5.370.20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clnu.2018.01.020","article-title":"Exclusive enteral nutrition in crohn's disease: evidence and practicalities","volume":"38","author":"Ashton","year":"2019","journal-title":"Clin Nutr"},{"key":"2024122723550890000_109.5.370.21","doi-asserted-by":"crossref","DOI":"10.3390\/nu12072018","article-title":"Dietary strategies for maintenance of clinical remission in inflammatory bowel diseases: are we there yet","volume":"12","author":"Gkikas","year":"2020","journal-title":"Nutrients"},{"key":"2024122723550890000_109.5.370.22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/ecco-jcc\/jjx109","article-title":"Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by D-ECCO working group","volume":"11","author":"Sigall-Boneh","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2024122723550890000_109.5.370.23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/jhn.12862","article-title":"The impact of national Lockdown on nutritional status of children with inflammatory bowel disease","volume":"34","author":"Marino","year":"2021","journal-title":"J Hum Nutr Diet"},{"key":"2024122723550890000_109.5.370.24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.gastro.2022.06.052","article-title":"Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis","volume":"163","author":"Nguyen","year":"2022","journal-title":"Gastroenterology"},{"key":"2024122723550890000_109.5.370.25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322339"},{"key":"2024122723550890000_109.5.370.26","first-page":"413","article-title":"Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn\u2019s disease","volume":"31","author":"Tsui","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2024122723550890000_109.5.370.27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/ecco-jcc\/jjy027","article-title":"Top-down in the long term in Crohn\u2019s disease","volume":"12","author":"Boyapati","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2024122723550890000_109.5.370.28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122723550890000_109.5.370.29","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2014-100527"},{"key":"2024122723550890000_109.5.370.30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.041"},{"key":"2024122723550890000_109.5.370.31","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.cgh.2022.01.019","article-title":"Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease","volume":"20","author":"Mahmoud","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024122723550890000_109.5.370.32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ecco-jcc\/jjy206","article-title":"Management of paediatric patients with medically refractory Crohn\u2019s disease using ustekinumab: a multi-centred cohort study","volume":"13","author":"Chavannes","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024122723550890000_109.5.370.33","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/ecco-jcc\/jjx082","article-title":"Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto group of ESPGHAN","volume":"11","author":"Ledder","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2024122723550890000_109.5.370.34","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312912"},{"key":"2024122723550890000_109.5.370.35","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2022-102130"},{"key":"2024122723550890000_109.5.370.36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MPG.0000000000003148","article-title":"Transition services for paediatric inflammatory bowel disease; a multicentre study of practice in the United Kingdom","volume":"73","author":"Ashton","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2023-325668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T02:56:43Z","timestamp":1735354603000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2023-325668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,18]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/archdischild-2023-325668"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2023-325668","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}